Respiratory and urinary tract infections, arthritis, and asthma associated with HTLV-I and HTLV-II infection.

Human T-lymphotropic virus types I and II (HTLV-I and -II) cause myelopathy; HTLV-I, but not HTLV-II, causes adult T-cell leukemia. Whether HTLV-II is associated with other diseases is unknown. Using survival analysis, we studied medical history data from a prospective cohort of HTLV-I--and HTLV-II-infected and -uninfected blood donors, all HIV seronegative. A total of 152 HTLV-I, 387 HTLV-II, and 799 uninfected donors were enrolled and followed for a median of 4.4, 4.3, and 4.4 years, respectively. HTLV-II participants had significantly increased incidences of acute bronchitis (incidence ratio [IR] = 1.68), bladder or kidney infection (IR = 1.55), arthritis (IR = 2.66), and asthma (IR = 3.28), and a borderline increase in pneumonia (IR = 1.82, 95% confidence interval [CI] 0.98 to 3.38). HTLV-I participants had significantly increased incidences of bladder or kidney infection (IR = 1.82), and arthritis (IR = 2.84). We conclude that HTLV-II infection may inhibit immunologic responses to respiratory infections and that both HTLV-I and -II may induce inflammatory or autoimmune reactions.

**********

Human T-lymphotropic virus types I and It (HTLV-I and -II) are presumed to have derived from primate T-lymphotropic viruses with which they share significant nucleotide sequence homology (1). They are transmitted by sexual intercourse; by parenteral modes such as unscreened blood or shared injection equipment; and from mother to child, predominantly by breast feeding (2-4). HTLV-I has been causally associated with adult T-cell leukemia and HTLV-associated myelopathy. HTLV-II has also been associated with HTLV-associated myelopathy, but not with leukemia (5).

Other possible health outcomes of chronic HTLV-I and -II infection have not yet been adequately investigated. Patients with adult T-cell leukemia may develop opportunistic infections such as Pneumocystis carinii pneumonia (6) or Strongyloides superinfection (7), but clinical immunodeficiency does not appear to develop in most persons with chronic HTLV-I or -II infection. On the contrary, syndromes suggestive of increased immunologic response such as uveitis (8), pneumonitis (9,10), and rarely, cases of lymphocytic arthritis (11,12) have been reported, although only uveitis has been epidemiologically associated with HTLV-I (8). Investigators in Japan have linked HTLV-I to a higher occurrence of various medical conditions (13) and virus-associated malignancies (14). Other investigators have reported an association between HTLV-II and pneumonia among injection drug users (15).

Case series and cross-sectional studies of HTLV-I and -II disease outcomes are vulnerable to potential bias and confounding. We have prospectively followed a large cohort of former blood donors with well-documented HTLV-I and -II infection at enrollment, and a similar group of uninfected donors, all of whom are HIV seronegative. We report on the occurrence of various disease outcomes in this cohort after a median follow-up of 4.3 years.

Methods

Study Design and Participants

This study is a prospective, multicenter cohort of persons with HTLV-I and -II infections, which were detected at the time of attempted blood donation at five U.S. blood centers and comparable HTLV--seronegative donors. Details of the cohort enrollment and follow-up procedures have been published previously (16,17). The study protocol was approved by the UCSF Committee on Human Research and by IRB at other participating institutions.

We determined HTLV serostatus by obtaining enzyme immunoassay test results followed by confirmatory Western blot. A central laboratory performed HTLV-I versus -II typing with a type-specific serologic assay, polymerase chain reaction (PCR), or both, as previously described (18). Unequivocal results from the type-specific serologic assay correlated well with those from the polymerase chain reaction assay. All participants were seronegative for HIV when baseline test were performed. For most participants, hepatitis C virus antibody status was not available at the time of enrollment.

Disease Endpoints

Each visit with a study nurse consisted of an interviewer-administered health history questionnaire and phlebotomy of blood for complete blood count and other studies. Selected diagnoses (cancer, neurologic and autoimmune conditions) reported on the questionnaire triggered requests for confirmatory medical records. We included nine conditions or diseases (pneumonia, acute bronchitis, bladder or kidney infection, arthritis, hypertension, asthma, cancer, diabetes, and thyroid disease) and eight symptoms (trouble walking, climbing, or rising from chair; incontinence; pre- or post-void urgency; lymphadenopathy; night sweats; weight loss; foot paresthesias; and impotence [males]) in the data analysis.

Statistical Analysis

We used the Kaplan-Meier product limit method to calculate the unadjusted probability of disease-free survival during the study period for each disease outcome by HTLV status. Survival time was defined as the number of days from the baseline visit until the date that an adverse health outcome was first diagnosed or the end of observation. We performed the log-rank test to assess the differences in disease-free survival time (days) between HTLV-seronegative participants and HTLV-I--or HTLV-II--infected participants, respectively.

To adjust for possible confounding factors, we performed multivariable analysis with HTLV status as an independent variable, survival time as a dependent variable, and possible confounding factors as covariates. In constructing the survival analysis models, we considered a number of covariates, which are described as follows: demographic variables (forced into all models), education, smoking history (pack-years, forced into the models for bronchitis and pneumonia), alcohol consumption, blood center, community versus autologous donation type, injection drug use (except in models for arthritis, hypertension, cancer, neurologic and urologic symptoms), parity (in models for urinary symptoms, bladder and kidney infections, and in females only), and number of sex partners (in model for bladder and kidney infections only). Using a backward selection process, all these covariates were added to the initial model, but only covariates with significant independent associations themselves (p < 0.05), or which substantively modified HTLV incidence ratio, were retained in the final model. We did not include interaction terms because similar analyses of data from prior cohort visits had indicated the absence of significant interaction.

To examine the differences in the cumulative number of episodes of pneumonia, bronchitis, and bladder or kidney infection by HTLV status, we used the negative binomial model, a generalization of the Poisson model, to compute incidence rate ratios (RR) with 95% confidence interval (CI) for each of these outcomes. This model took into account that the recurrence of the disease in a participant may be associated with both the overall disease incidence and its previous occurrence in that participant. We also adjusted for possible confounding factors using the same modeling strategy as for the survival analyses.

For the analysis of symptoms, we calculated unadjusted and adjusted odds ratio (OR) with 95% CI for any occurrence of each symptom by HTLV status by using logistic regression models. To adjust for possible confounding, we added other possible confounding factors as covariates to the models by using the same approach as in the survival analyses. All analyses were performed using Statistical Analysis System (SAS) software (19).

Results

Study Population and Follow-up

During the initial visits in 1990 through 1992, we enrolled 154 HTLV-I, 387 HTLV-II, and 799 HTLV seronegative persons. Two HTLV-I participants were excluded from this analysis because they did not complete the screening physical examination at the initial visit. The baseline characteristics of the study population are given in Table 1. The HTLV groups and seronegative participants were comparable with respect to age, sex, race or ethnicity, blood center visited, and type of blood donation (autologous versus allogeneic), except for slightly higher proportions of blacks among the HTLV-I group and Hispanics among the HTLV-II group. The HTLV-II group had the lowest socioeconomic status, as indicated by educational attainment and income, and the HTLV-I group had intermediate status. Pack-years of cigarette smoking and amount of alcohol intake were higher in the HTLV-II group. Consistent with the recognized epidemiologic risk Factors for HTLV-I and -II infection (3,4), the HTLV-I and -II groups had more lifetime sexual partners than seronegative participants, and almost 24% of the HTLV-II participants had a lifetime history of injection drug use, although only 4.4% of the HTLV-II group admitted to current injection drug use.

We present data through the third study visit in 1995 through 1996. Median follow-up time was 4.3 years for all 1,338 participants, including those with no follow-up. Median follow-up did not differ by HTLV status and was 4.4 years for the HTLV-I group, 4.3 years for the HTLV-II group, and 4.4 years for the HTLV-seronegative group.

HTLV-I Findings

Compared to seronegative persons, HTLV-I--infected persons were more likely to have a new diagnosis of bladder or kidney infection (p = 0.009) and arthritis (p = 0.0002) (Figure). Among the HTLV-I--infected persons, two had asthma; an insufficient number to test the difference relative to seronegative persons. The HTLV-I participants showed no statistically significant differences in the incidence of pneumonia, acute bronchitis, and hypertension, cancer, diabetes, and thyroid disease (data not shown).

The number of incident cases diagnosed (limited to one case per person) and the unadjusted and adjusted incidence ratios (IR) for several diagnoses are given in Table 2. Compared with results for seronegative persons, and after multivariable adjustment for relevant confounding variables, HTLV-I infection was associated with bladder or kidney infection (IR 1.82, 95% CI 1.19 to 2.77) and arthritis (IR 2.84, 95% CI 1.51 to 5.33). The risks of developing pneumonia, acute bronchitis, hypertension, and cancer were not significantly increased. Too few cases of asthma (n = 2), thyroid disease (n = 1), and diabetes mellitus (n = 5) existed among the HTLV-I participants to perform survival analysis.

To further investigate the occurrence of infectious diseases, we also analyzed the incidence density of three infectious diseases by HTLV status, whether or not each diagnosis was a first or recurrent case (Table 3). In the incidence density analysis (Table 3), an average of 1.75 cases of bladder or kidney infection occurred per HTLV-I participant over the 4.4-year median follow-up time, compared with 0.63 per seronegative participant over the same period. The unadjusted and adjusted RRs for the HTLV-I group were significantly greater than unity for bladder or kidney infection. HTLV-I participants had increased prevalence rates of neurologic symptoms, self-reported lymphadenopathy, and night sweats, but they reported weight loss no more frequently than did HTLV-seronegative persons (Table 4).

HTLV-II Findings

Disease-free survival curves for selected medical diagnoses, by HTLV status, are represented in the Figure. Compared to seronegative persons, HTLV-II--infected participants were more likely to experience acute bronchitis (p < 0.0001), bladder or kidney infection (p = 0.0008), arthritis (p = 0.0003), and asthma (p = 0.0007); the likelihood of acquiring pneumonia was increased but not significantly (p = 0.08). Differences between the HTLV-II and HTLV-seronegative participants in the incidence of cancer, hypertension, diabetes, or thyroid disease were not statistically significant.

The number of incident cases diagnosed (limited to one case per participant), and the unadjusted and adjusted IRs, for several diagnoses are given in Table 2. Compared with results for seronegative participants, and after adjusting for confounding variables, HTLV-II was associated with acute bronchitis (OR 1.68, 95% CI 1.24 to 2.29), bladder or kidney infection (OR 1.55, 95% CI 1.14 to 2.11), arthritis (OR 2.66, 95% CI 1.58 to 4.45), and asthma (OR 3.28, 95% CI 1.57 to 6.84). The association between HTLV-II infection and pneumonia was of borderline statistical significance (IR 1.82,95% CI 0.98 to 3.38). IRs for hypertension and cancer were not increased for HTLV-II participants. Too few cases of thyroid disease (n = 7) and diabetes mellitus (n = 7) were found among the HTLV-II participants to perform survival analysis.

In the incidence density analysis of recurrent infections, an average of 0.21 cases of pneumonia, 1.10 cases of acute bronchitis, and 1.25 cases of bladder or kidney infection occurred among HTLV-II participants during their 4.3-year median follow-up time (Table 3). The corresponding incidence densities for the seronegative group were 0.08, 0.59, and 0.63, respectively, over their 4.4 year median follow-up time. Both unadjusted and adjusted RRs, calculated by using negative binomial modeling, were significantly greater than unity for all three diseases (Table 3). Compared with seronegative participants, HTLV-II participants had increased prevalence rates of several neurologic, lymphatic, and constitutional symptoms, but the prevalence of impotence (males) was not significantly increased (Table 4).

Discussion

In summary, HTLV-II--infected participants had a higher incidence of acute bronchitis, bladder or kidney infection, arthritis and asthma, and a higher incidence of pneumonia than did HTLV-seronegative participants followed concurrently. The finding of a higher rate of these infectious diseases among HTLV-II participants was supported both by survival analysis, which considered only the first diagnosis, and by negative binomial modeling, which considered both first and recurrent infections. HTLV-I participants had a higher incidence of bladder or kidney infection and arthritis. Cancer incidence was not higher in either the HTLV-I or HTLV-II participants compared to its incidence in seronegative participants, although the number of cases was small.

Our finding of a higher incidence of respiratory tract infections among HTLV-II--infected persons is consistent with most of the small number of other published clinical studies on this topic. Robert-Guroff et al. found higher rates of HTLV-II infection among injection drug users with abscess than in those without abscess (20). In another cross-sectional analysis, Modahl et al. found that injection drug users with HTLV-II infection were more likely to have been diagnosed with pneumonia, abscess, or lymphadenopathy (15), although a subsequent case-control study did not find that either HTLV-II or HIV are risk factors for skin and soft tissue abscess among injection drug users (21). LaGrenade et al. have documented an association between HTLV-I infection and Staphylococcus- and Streptococcus-related infective dermatitis among Jamaican children (22). An independent nested case-control study of pneumonia, abscess, and endocarditis among Baltimore injection drug users found no association between these infections and HTLV-II seropositivity (23). A number of opportunistic co-infections have been reported in conjunction with HTLV-I infection, including Strongyloides hyperinfection (7), P. carinii pneumonia (in patients with HTLV-I related adult T-cell leukemia) (6), and leprosy (24).

The biologic basis for a putative increased susceptibility to certain infections in humans with chronic HTLV-II infection is not well described. In contrast to the predominant CD4+ lymphotropism of HTLV-I, HTLV-II provirus in vivo is integrated at highest levels into CD8+ lymphocytes but may also be demonstrated in CD4+, both CD45RO+ and CD45RO-, and even non-T (CD14, CD16, and CD19) lymphocytes (25). Delayed hypersensitivity response to mumps virus and Candida antigens is normal among HTLV-II participants, suggesting intact cell-mediated or T-helper 1-type immunity (26). Although subtle differences may exist, the overall distribution of lymphocyte subsets is not perturbed in persons with HTLV-II (27,28). However, total immunoglobulin G levels are higher in HTLV-II-infected persons (29), in vitro cell proliferation in response to pokeweed mitogen is suppressed in HTLV-II infection (28), and HTLV-II may induce expression of interferon-[gamma], granulocyte macrophage-colony-stimulating factor, and other cytokines (30,31). Although HTLV-II provirus has also been demonstrated in macrophages (32), whether such infection influences macrophage regulation or function to a clinically notable degree is not known. Finally, lymphocytic pneumonitis has been reported in association with HTLV-I infection (9,10), and clinically diagnosed cases of pneumonia and acute bronchitis in HTLV-II- infected persons could conceivably represent autoimmune rather than infectious disease.

Our finding of an association of both HTLV-II and HTLV-I with bladder or kidney infection is consistent with a previous report of unspecified renal disease in a prospective cohort study of HTLV-I-infected persons in Japan (33). However, such associations must be interpreted cautiously in light of the known association of both retroviruses with HTLV-associated myelopathy (5,34,35). Since urinary frequency and urgency are among the first symptoms of bladder hyperreactivity due to the underlying myelopathy, HTLV-I- or -II-infected persons might seek medical care for these symptoms. Urinary tract infection or kidney disease secondary to unrecognized neurogenic bladder dysfunction might be diagnosed, or they may be treated presumptively for urinary tract infection on the basis of their bladder symptoms. In either case, an increased incidence of diagnosed bladder or kidney infection may not necessarily indicate that HTLV-I or -II infection is the cause of these urinary infections. Finally, although we controlled for the number of sexual partners, residual confounding by sexual activity could have influenced our bladder or kidney infection finding (36).

The increased incidence of arthritis observed for both persons infected with HTLV-I and HTLV-II supports reports of possible autoimmune syndromes with HTLV infection. HTLV-I has been epidemiologically associated with uveitis (8). Several previous reports of HTLV-I in case series of arthritis have been limited by the lack of appropriate controls (11,12). Nonetheless, high numbers of HTLV-I-infected lymphocytes have been demonstrated in synovial fluid from some of these case-patients. Although we obtained medical records to verify arthritis and other diagnoses, the records did not give sufficient information to classify the type of arthritis and diagnostic evaluations were limited in most cases. Although an association between HTLV-I infection and asthma has been reported among Japanese men (13), we are unaware of previous reports of an increased incidence of asthma in association with HTLV-II infection. Also, a few cases of lymphocytic pneumonitis have been reported in patients with HTLV-I infection, particularly those with myelopathy (9,10). We plan a more intensive diagnostic evaluation of the HTLV-II participants in this study with recurrent pneumonia or asthma to explore the possible contribution of undiagnosed lymphocytic pneumonitis to the observed clinical signs and symptoms.

We have previously reported a single case of adult T-cell leukemia which was diagnosed between the first and second visits of the patient in this cohort study (17); no additional cases have been diagnosed to date. That neither HTLV-I nor -II participants had an increased incidence of nonhematologic cancer in our current analysis is potentially reassuring to persons infected with these retroviruses. However, an increased incidence of some cancers, especially those thought to be induced by viruses, has been reported in a Japanese HTLV-I cohort (37). We might not have detected a small increase in IR because of the relatively small number of cases detected during our 4.3-year follow-up period. Alternatively, we might not have had enough HTLV-I or -II participants who were co-infected with other oncogenic viruses such as hepatitis C virus to detect a synergistic effect between HTLV-I or -II and these viruses (38).

The two- to three-fold higher prevalence of self-reported neurologic symptoms, including trouble walking, climbing stairs, or rising from a chair, and bladder symptoms may represent early spinal cord injury due to HTLV-I or -II. As follow-up of the cohort continues, we shall be able to determine whether those reporting such symptoms in earlier visits have a higher incidence of overt myelopathy than asymptomatic HTLV-infected participants. On the other hand, the frequency of self-reported lymphadenopathy and night sweats is unlikely to be caused by preclinical hematologic malignancy, given the rarity of that disorder in HTLV-I--infected persons and its lack of association with HTLV-II. These symptoms might be related to known effects of HTLV-I and -II on lymphocytic proliferation and cytokine expression, or they might simply reflect reporting bias.

Strengths of the current study include its controlled, prospective, cohort design, stringent confirmation of HTLV-I--and -II--infection status at baseline, and systematic ascertainment of disease outcomes. One potential weakness is that differences in socioeconomic status and risk behaviors could have confounded disease associations between HTLV--infected and uninfected previous blood donors, even though we selected the uninfected participants in strata defined by the age, sex, race or ethnicity, center, and blood donation type of the HTLV groups. We controlled for the socioeconomic and behavioral factors using multivariate analyses, but residual confounding could affect the magnitude of the associations we observed. Second, recall bias may exist in that participants with HTLV infection might differentially report more diagnoses because of heightened concern about their own health. Our questionnaire requested only medically confirmed diagnoses, and the absence of associations with noninfectious disease, such as hypertension, diabetes, and thyroid disease, suggests that generalized overreporting of illness was not a problem. Additionally, infectious disease associations with HTLV have not been widely reported, so we do not think that recall bias specific to these diagnoses was a serious concern. Finally, follow-up time to date is modest for a chronic infection such as HTLV, and our findings may change with longer observation.

In conclusion, HTLV-II infection is associated with an increased incidence of respiratory and urinary tract infections and asthma, and both HTLV-I and -II are associated with increased incidence rates of arthritis, compared with results for seronegative persons. These findings suggest that chronic infection with HTLV-II may inhibit host immunologic responses to infection, or more specifically, to respiratory infections. The arthritis and asthma results, and possibly the respiratory tract diagnoses, suggest that other inflammatory or autoimmune reactions may be induced by HTLV-I or HTLV-II infection. Additional in vitro and in vivo research on the immunologic consequences of HTLV infection is needed.

Acknowledgments

We thank Erica Arnold, Dolores Behan, Leslee Gold, Kathleen Naiman, Janis Campbell, Shirley McElfresh, MaryJanice Arceo, Eva Dupree, Debra Littner, Peggy Richie, Alberta Rodney, Clary Charleston, Patricia Crawley, Dezreen MacDowell, Kay Sclimenti, Diana Wilke, Marilyn Boros, Anne Guiltinan, Rebecca Ruedy, Debbie DeVita, Brena Argo, Elane Moore, Donna Smith, Dannie Ameti, Susan Yuen, and the study participants at all five centers for their ongoing participation in this long-term study.

Data analysis and manuscript preparation were funded by a grant (R01-HL-62235) from the National Heart, Lung and Blood Institute (NHLBI). Data collection was supported by the Retrovirus Epidemiology Donor Study (REDS) under contracts N01-HB-47114, -97078, -97079, -97080, -97081, and -97082, also from NHLBI.

Table 1. Characteristics of the multicenter, prospective human
T-lymphotropic virus (HTLV) cohort study population (a)

                                                     HTLV
                            HTLV-I      HTLV-II    negative
Characteristics            (n = 152)   (n = 387)   (n = 799)

Age (y)                     No. (%)     No. (%)     No. (%)
  18-29                      5 (3)      11 (3)      34 (4)
  30-39                     28 (18)    104 (27)    171 (21)
  40-49                     55 (36)    168 (43)    288 (36)
  50-59                     32 (21)     73 (19)    175 (22)
  [greater than             32 (21)     31 (8)     131 (16)
    or equal to] 60
Sex
  Male                      43 (28)    102 (26)    257 (32)
  Female                   109 (72)    285 (74)    542 (68)
Race/ethnicity
  Asian                     20 (13)      8 (2)      60 (8)
  Black                     61 (40)    125 (32)    248 (31)
  Hispanic                   9 (6)     104 (27)    150 (19)
  Other                      1 (1)       7 (2)      30 (4)
  White                     59 (39)    140 (36)    309 (39)
  Unknown                    2 (1)       3 (1)       2 (0)
Education
  High school or less       45 (30)    135 (35)    129 (16)
  Some college              66 (43)    195 (51)    363 (46)
  College                   30 (20)     45 (12)    181 (23)
  College (>4 years)        11 (7)      11 (3)     123 (15)
Income
  <$30,000                  46 (30)    144 (38)    167 (21)
  $30,000-49,999            51 (34)    120 (32)    221 (28)
  [greater than             55 (36)    113 (30)    401 (51)
    or equal to] $50,000
Center
  1                         32 (21)     51 (13)    122 (15)
  2                         29 (19)     39 (10)    102 (13)
  3                         44 (29)    206 (53)    345 (43)
  4                         31 (20)     68 (18)    156 (20)
  5                         16 (11)     23 (6)      74 (9)
Blood donor type
  Autologous                28 (18)     39 (10)    111 (14)
  Allogeneic               124 (82)    348 (90)    688 (86)
Smoking history (pack/y)
  Nonsmoker                 74 (52)    125 (36)    413 (54)
  0-13                      24 (17)    117 (33)    184 (24)
  >13                       43 (31)    109 (31)    174 (23)
Alcohol intake (average
    drinks per wk)
  Nondrinker                19 (13)     20 (6)      70 (9)
  0-1                       58 (41)    134 (38)    352 (46)
  >1                        64 (45)    200 (57)    339 (45)
Lifetime sex partners
  <6                        56 (38)     87 (23)    381 (49)
  [greater than             92 (62)    292 (77)    403 (51)
    or equal to] 6
Injection drug use
  Ever                     148 (98)    294 (76)    787 (99)
  Ex-injection drug user     2 (1)      75 (19)      9 (1)
  Current injection drug     1 (1)      17 (4)       1 (0)
    user

(a) Missing data (up to 6%, depending upon the variable) were
excluded from the calculation of percentages.

Table 2. Incidence of medically diagnosed conditions and selected
unadjusted and adjusted incidence ratios among human T-lymphotropic
virus (HTLV)-I--and HTLV-II--infected participants and
HTLV-seronegative participants, visits 2 and 3 (a)

                        HTLV
                    seronegative
                      (N = 799)        HTLV-I (N = 152)

Diagnosis           Cases (% (b))   Cases (% (b))   IR (c)

Pneumonia              25 (3)           5 (4)       0.89
Acute bronchitis      103 (14)         21 (15)      1.12
Bladder or kidney     105 (14)         31 (23)      1.74
  infection
Arthritis              32 (5)          16 (16)      3.19
Hypertension           40 (7)           7 (7)       1.06
Asthma                 15 (2)           2 (2)        --
Cancer                 21 (3)           3 (2)       0.81

                      HTLV-I (N = 152)       HTLV-II (N = 387)

Diagnosis           Adj. IR (95% CI) (d)   Cases (% (b))   IR (c)

Pneumonia           0.79 (0.27 to 2.29)       19 (5)        1.70
Acute bronchitis    1.10 (0.68 to 1.79)       81 (23)       1.83
Bladder or kidney   1.82 (1.19 to 2.77)       73 (21)       1.68
  infection
Arthritis           2.84 (1.51 to 5.33)       32 (12)       2.51
Hypertension        0.99 (0.44 to 2.22)       20 (7)        1.08
Asthma                       --               20 (6)        3.38
Cancer              0.72 (0.21 to 2.43)        8 (2)        0.87

                      HTLV-II (N = 387)

Diagnosis           Adj. IR (95% CI) (d)

Pneumonia           1.82 (0.98 to 3.38)
Acute bronchitis    1.68 (1.24 to 2.29)
Bladder or kidney   1.55 (1.14 to 2.11)
  infection
Arthritis           2.66 (1.58 to 4.45)
Hypertension        1.09 (0.63 to 1.89)
Asthma              3.28 (1.57 to 6.84)
Cancer              1.10 (0.44 to 2.32)

(a) Only the first diagnosis of each condition is considered for
each participant. IR, incidence ratio derived from survival
analysis; CI, confidence interval.

(b) Denominator for percentage calculation varied according to
the number of participants included in each disease-specific
analysis.

(c) Unadjusted incidence ratio derived from survival analysis.

(d) After a backward selection process, including all potential
confounding variables, the final survival analysis model contained
these variables: age, gender, race/ethnicity, and (for pneumonia,
bronchitis, and asthma) smoking history (see Methods for derails of
the statistical analysis).

Table 3. Incidence density (ID) (a) and standard deviation (SD)
of medically diagnosed infectious diseases, and selected crude
and adjusted rate ratios (RR), among human T-lymphotropic virus
(HTLV)-I--and HTLV-II--infected participants and HTLV-seronegative
participants, visits 2 and 3

                        HTLV
                    seronegative
                     (N = 799)      HTLV-I (N = 152)

Diagnosis             ID (SD)        ID (SD)     RR (b)

Pneumonia           0.08 (0.37)    0.11 (0.47)    1.49
Acute bronchitis    0.59 (1.78)    0.82 (2.25)    1.38
Bladder or kidney   0.63 (2.04)    1.75 (4.61)    2.73
  infection

                      HTLV-I (N = 152)      HTLV-II (N = 387)

Diagnosis           Adj. RR (95% CI) (c)     ID (SD)     RR (b)

Pneumonia           1.33 (0.66 to 2.66)    0.21 (0.96)    2.82
Acute bronchitis    1.33 (0.84 to 2.12)    1.10 (2.75)    1.83
Bladder or kidney   2.32 (1.50 to 3.59)    1.25 (3.48)    1.94
  infection

                     HTLV-II (N = 387)

Diagnosis           Adj. RR (95% CI) (c)

Pneumonia           2.65 (1.67 to 4.21)
Acute bronchitis    1.53 (1.10 to 2.14)
Bladder or kidney   1.94 (1.40 to 2.68)
  infection

(a) Defined as the mean of the total number of infectious disease
diagnoses divided by the number of participants (with or without
the infection) in each group at baseline. The period of observation
was 4.4 years (HTLV-I), 4.3 years (HTLV-II), and 4.4 years (HTLV
seronegative), and each participant may have multiple diagnoses of
each condition.

(b) Unadjusted.

(c) Adjusted. Adjusted models included age, gender, race/ethnicity
and duration of follow-up for all infections, and injection drug
use (for pneumonia), smoking (for acute bronchitis), and community
versus autologous blood donation (for bladder/kidney infection).

Table 4. Prevalence of medically diagnosed symptoms, and unadjusted
and adjusted odds ratios (OR) derived from logistic regression
models, in human T-lymphotropic virus (HTLV)-I--and HTLV-II--

infected participants and HTLV-seronegative participants, visits
2 and 3 (a)

                                  HTLV
                              seronegative
                                (N = 799)        HTLV-I (N = 152)

Symptoms                      Cases (%) (b)   Cases (%) (b)   OR (c)

Trouble walking, climbing
  or rising from chair          147 (21)         52 (42)       2.71
Incontinence, pre- or post-
  void urgency                  175 (25)         50 (40)       2.03
Lymphadenopathy                  29 (4)          11 (9)        2.26
Night sweats                     20 (3)          15 (12)       4.68
Weight loss                      40 (6)           9 (7)        1.29
Foot paresthesias                57 (8)          22 (18)       2.44
Impotence (males only)           33 (5)          10 (8)        2.24

                                                        HTLV-II
                                                       (N = 387)
                              HTLV-I (N = 152)
Symptoms                      Adj. OR (95% CI) (d)   Cases (%) (b)

Trouble walking, climbing
  or rising from chair        2.67 (1.74 to 4.09)      133 (42)
Incontinence, pre- or post-
  void urgency                2.02 (1.33 to 33.07)     134 (43)
Lymphadenopathy               2.39 (1.14 to 5.03)       40 (13)
Night sweats                  4.73 (2.31 to 9.69)       47 (15)
Weight loss                   1.10 (0.51 to 2.37)       40 (13)
Foot paresthesias             2.46 (1.41 to 4.28        66 (21)
Impotence (males only)        2.05 (0.77 to 5.49)       13 (4)

                                     HTLV-II (N = 387)

Symptoms                      OR (c)   Adj. OR (95% CI) (d)

Trouble walking, climbing
  or rising from chair         2.78     3.44 (2.52 to 4.71)
Incontinence, pre- or post-
  void urgency                 2.25     2.59 (1.92 to 3.49)
Lymphadenopathy                3.40     3.08 (1.85 to 5.13)
Night sweats                   6.02     4.97 (2.77 to 8.94
Weight loss                    2.43     2.10 (1.22 to 3.60)
Foot paresthesias              3.02     3.27 (2.19 to 4.88)
Impotence (males only)         1.10     1.27 (0.56 to 2.91)

(a) Only the first diagnosis of each symptom is considered for each
participant.

(b) Denominator for percentage calculation varied according to the
number of participants included in each disease-specific analysis.

(c) Unadjusted.

(d) Adjusted. Models were adjusted for age, race and ethnicity, and
duration of follow-up (all symptoms), and gender (all except
impotence). In addition, specific models included community versus
autologous donation (for trouble walking and incontinence, weight
loss and impotence) and injection drug use [night sweats and weight
loss]).

References

(1.) Slattery JP, Franchini G, Gessain A. Genomic evolution, patterns of global dissemination, and interspecies transmission of human and simian T-cell leukemia/lymphotropic viruses. Genome Res 1999;9:525-40.

(2.) Manns A, Hisada M, La Grenade L. Human T-lymphotropic virus type I infection. Lancet 1999;353:1951-8.

(3.) Gebretsadik T, Murphy EL. Counseling and medical evaluation of HTLV-I- and HTLV-II-infected patients. AIDS Clin Rev 1993-94:19-41.

(4.) Hall WW, Ishak R, Zhu SW, Novoa P, Eiraku N, Takahashi H, et el. Human T lymphotropic virus type II (HTLV-II): epidemiology, molecular properties, and clinical features of infection. J Acquir Immune Defic Syndr Hum Retrovirol 1996;13(Suppl 1):S204-14.

(5.) Murphy EL, Fridey J, Smith JW, Engstrom J, Sachet RA, Miller K, et el. HTLV-associated myelopathy in a cohort of HTLV-I and HTLV-II infected blood donors. Neurology 1997;48:315-20.

(6.) Marutsuka K, Suzumiya J, Sumiyoshi A. Cavitating Pneumocystis pneumonia in an autopsied case of adult T-cell leukemia. Int J Hematol 1992;56:233-7.

(7.) Robinson RD, Lindo JF, Neva FA, Gam AA, Vogel P, Terry SI, et al. Immunoepidemiologic studies of Strongyloides stercoralis and human T lymphotropic virus type I infections in Jamaica. J Infect Dis 1994;169:692-6.

(8.) Watanabe T, Mochizuki M, Yamaguchi K. HTLV-I uveitis (HU). Leukemia 1997;11 (Suppl 3):582-4.

(9.) Sugimoto M, Nakashima H, Watanabe S, Uyama E, Tanaka F, Ando M, et al. T-lymphocyte alveolitis in HTLV-I-associated myelopathy. Lancet 1987;2:1220.

(10.) Mita S, Sugimoto M, Nakamura M, Murakami T, Tokunaga M, Uyama E, et al. Increased human T lymphotropic virus type-1 (HTLV-1) proviral DNA in peripheral blood mononuclear cells and bronchoalveolar lavage cells from Japanese patients with HTLV-1-associated myelopathy. Am J Trop Med Hyg 1993;48:170-7.

(11.) Nishioka K. HTLV-I arthropathy and Sjogren syndrome. J Acquir Immune Defic Syndr Hum Retrovirol 1996;13(Suppl 1):S57-52.

(12.) McCallum RM, Patel DD, Moore JO, Haynes BF. Arthritis syndromes associated with human T cell lymphotropic virus type I infection. Med Clin North Am 1997;81:261-76.

(13.) Stuver SO, Tachibana N, Okayama A, Mueller NE. Evaluation of morbidity among human T lymphotropic virus type 1 carriers in Miyazaki, Japan. J Infect Dis 1996;173:584-91.

(14.) Stuver SO, Okayama A, Tachibana N, Tsubouchi H, Mueller NE, Tabor E. HCV infection and liver cancer mortality in a Japanese population with HTLV-I. Int J Cancer. 1996;67:35-7.

(15.) Modahl LA, Young K, Varney K, Khayam-Bashi H, Murphy EL. Are HTLV-II-seropositive injection drug users at increased risk for bacterial pneumonia, abscess and lymphadenopathy? J Acq Immun Defic Syndr Hum Retrovirol 1997;16:169-75.

(16.) Murphy EL, Glynn S, Fridey J, Sacher RA, Smith J, Wright DJ, et al. Increased prevalence of infectious diseases and other adverse outcomes in human T lymphotropic virus types I- and II-infected blood donors. Retrovirus Epidemiology Donor Study (REDS) Study Group. J infect Dis 1997;176:1468-75.

(17.) Murphy EL, Glynn SA, Fridey J, Smith JW, Sachet RA, Nass CC, et al. Increased incidence of infectious diseases and neurologic abnormalities during prospective follow-up of HTLV-II and -I infected blood donors. Arch Intern Med 1999;159:1485-91.

(18.) Busch MP, Laycock M, Kleinman SH, Wages JW Jr, Calabro M, Kaplan JE, et al. Accuracy of supplementary serologic testing for human T-lymphotropic virus types I and II in US blood donors. Retrovirus Epidemiology Donor Study. Blood 1994;83:1143-8.

(19.) SAS Institute, Inc., SAS/STAT(r) user's guide, version 8, Cary, NC: SAS Institute Inc.; 1999.

(20.) Robert-Guroff M, Weiss SH, Giron JA, Jennings AM, Ginzburg HM, Margolis IB, et al. Prevalence of antibodies to HTLV-I, -II, and -III in intravenous drug abusers from an AIDS endemic region. JAMA 1986;255:3133-7.

(21.) Murphy EL, DeVita D, Liu H, Vittinghoff E, Leung P, Ciccarone DH, et al. Risk factors for skin and soft-tissue abscesses among injection drug users: a case-control study. Clin Infect Dis 2001;33:35-40.

(22.) LaGrenade L, Hanchard B, Fletcher V, Cranston B, Blattner W. Infective dermatitis of Jamaican children: a marker for HTLV-I infection. Lancet 1990;336:1345-7.

(23.) Safaeian M, Wilson LE, Taylor E, Thomas DL, Vlahov D. HTLV-II and bacterial infections among injection drug users. J Acquir Immune Defic Syndr 2000;24:483-7.

(24.) Marsh BJ. Infectious complications of human T cell leukemia/lymphoma virus type I infection. Clin Infect Dis 1996;23:138-45.

(25.) Lal RB, Owen SM, Rudolph DL, Dawson C, Prince H. In vivo cellular tropism of human T-lymphotropic virus type II is not restricted to CD8+ cells. Virology 1995;210:441-7.

(26.) Murphy EL, Wu Y, Ownby HE, Smith JW, Ruedy RK, Thomson RA, et al. Delayed hypersensitivity skin testing to mumps and Candida albicans antigens is normal in middle-aged HTLV-I- and-II-infected U.S. cohorts. AIDS Res Hum Retroviruses 2001;17:1273-7.

(27.) Prince HE, Jensen ER, York J. Lymphocyte subsets in HTLV-II-infected former blood donors: relationship to spontaneous lymphocyte proliferation. Clin Immunol Immunopathol 1992;65:201-6.

(28.) Klimas NG, Page JB, Patarca R, Chitwood D, Morgan R, Fletcher MA. Effects of retroviral infections on immune function in African-American intravenous drug users. AIDS 1993;7:331-5.

(29.) Rosenblatt JD, Plaeger-Marshall S, Giorgi JV, Swanson P, Chen IS, Chin E, et al. A clinical, hematologic, and immunologic analysis of 21 HTLV-II-infected intravenous drug users. Blood 1990;76:409-17.

(30.) Bovolenta C, Pilotti E, Mauri M, Turci M, Ciancianaini P, Fisicaro P, et al. Human T-cell leukemia virus type 2 induces survival and proliferation of CD34(+) TF-1 cells through activation of STAT1 and STAT5 by secretion of interferon-gamma and granulocyte macrophage-colony-stimulating factor. Blood 2002;99:224-31.

(31.) Lewis MJ, Gautier VW, Wang XP, Kaplan MH, Hall WW. Spontaneous production of C-C chemokines by individuals infected with human T lymphotropic virus type II (HTLV-II) alone and HTLV-II/HIV-1 coinfected individuals. J Immunol 2000;165:4127-32.

(32.) Zehender G, Meroni L, Varchetta S, De Maddalena C, Cavalli B, Gianotto M, Bet al. Human T-lymphotropic virus type 2 (HTLV-2) provirus in circulating cells of the monocyte/macrophage lineage in patients dually infected with human immunodeficiency virus type 1 and HTLV-2 and having predominantly sensory polyneuropathy. J Virol 1998;72:7664-8.

(33.) Stuver SO, Tachibana N, Okayama A, Mueller NE. Evaluation of morbidity among human T lymphotropic virus type 1 carriers in Miyazaki, Japan. J Infect Dis 1996;173:584-91.

(34.) Gessain A, Barin F, Vernant JC, Gout O, Maurs L, Calender A, et al. Antibodies to human T-lymphotropic virus type-I in patients with tropical spastic paraparesis. Lancet 1985;2:407-10.

(35.) Osame M, Usuku K, Izumo S, Ijichi N, Amitani H, Igata A, et al. HTLV-I associated myelopathy, a new clinical entity. Lancet 1986;1:1031-2. 36.

(36.) Stamm WE, Norrby SR. Urinary tract infections: disease panorama and challenges. J Infect Dis 2001;183(Suppl 1):S1-4.

(37.) Stuver SO, Okayama A, Tachibana N, Tsubouchi H, Mueller NE, Tabor E. HCV infection and liver cancer mortality in a Japanese population with HTLV-I. Int J Cancer 1996;67:35-7.

(38.) Boschi-Pinto C, Stuver S. Okayama A, Trichopoulos D, Orav EJ, Tsubouchi H, et al. A follow-up study of morbidity and mortality associated with hepatitis C virus infection and its interaction with human T lymphotropic virus type I in Miyazaki, Japan. J Infect Dis 2000;181:35-41.

Dr. Murphy is professor of Laboratory Medicine and Epidemiology/Biostatistics at University of California San Francisco; his laboratory is located at Blood Centers of the Pacific in San Francisco. His research interests are the epidemiology of viral infections of humans, particularly human T-lymphotropic virus-I and -II and transfusion-transmitted viruses, such as HIV, hepatitis B, and hepatitis C.

Address for correspondence: Edward L. Murphy, Laboratory Medicine and Epidemiology/Biostatistics, University of California San Francisco, Blood Centers of the Pacific, 270 Masonic Avenue, San Francisco, CA 94118, USA; fax: [phone]; email: [e-mail]

Edward L. Murphy, * Baoguang Wang, ([dagger]) Ronald A. Sacher, ([double dagger]) Joy Fridey, ([section]) James W. Smith, ([paragraph]) Catharie C. Nass, (#) Bruce Newman, ** Helen E. Ownby, ** George Garratty, ([dagger] [dagger]) Sheila T. Hutching, ([dagger] [dagger]) and George B. Schreiber ([dagger])

* University of California San Francisco, California, USA; ([dagger]) Westat, Rockville, Maryland, USA; ([double dagger]) Hoxworth Blood Center, Cincinnati, Ohio, USA; ([section]) Blood Bank of San Bernardino and Riverside Counties, San Bernardino, California, USA; ([paragraph]) Oklahoma Blood Institute, Oklahoma City, Oklahoma, USA; (#) American Red Cross Blood Services Chesapeake and Potomac, Baltimore, Maryland, USA; ** American Red Cross Blood Services Southeastern Michigan, Detroit, Michigan, USA; and ([dagger] [dagger]) American Red Cross Blood Services Southern California, Los Angeles, California, USA